The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women

Table 5 The effect of a treatment type on BMD change

Treatment type	Skeletal site	BMD before treatment	BMD after treatment	BMD difference after treatment	Sig. (P value)
HT	FN T-score	−2.132 ± 0.044	−1.784 ± 0.041	0.347 ± 0.043	0.001
	FN BMD	0.603 ± 0.06	0.649 ± 0.05	0.046 ± 0.05 (+ 7.3%)	0.001
	LS T-score	−2.871 ± 0.044	− 2.184 ± 0.048	0.687 ± 0.057	0.001
	LS BMD	0.674 ± 0.005	0.755 ± 0.005	0.081 ± 0.006 (+ 11.3%)	0.001
raloxifene	FN T-score	−2.155 ± 0.059	−1.913 ± 0.078	0.242 ± 0.070	0.002
	FN BMD	0.597 ± 0.008	0.635 ± 0.010	0.038 ± 0.009 (+ 5.2%)	0.002
	LS T-score	−2.947 ± 0.054	−2.484 ± 0.070	0.463 ± 0.063	0.001
	LS BMD	0.670 ± 0.007	0.725 ± 0.008	0.055 ± 0.007 (+ 7.7%)	0.001

BMD of femoral neck (FN) and lumbal spine (LS) is expressed as Estimated Marginal Mean ± SE (SE – standard error of the mean) of T-score (FN and LS T-score) and g/cm² (FN and LS BMD); HT – hormone therapy (17ß estradiol/progesterone); Sig. – significance of BMD difference after treatment, P values determine significant differences (P < 0.05)

ISSN: 1471-2350